Baird lowered the firm’s price target on Cencora (COR) to $392 from $395 and keeps an Outperform rating on the shares. The firm updated its model following its announced acquisition of OneOncology.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Strategic Acquisition: Hold Rating Amid Limited Near-Term Financial Upside
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
- Cencora backs FY26 adjusted EPS view $17.45-$17.75, consensus $17.67
- Cencora Announces Acquisition of OneOncology for $3.6 Billion
- Cencora to acquire OneOncology from TPG for $6B